Health Policy

The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma

Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews

South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.

The European Commission has approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making Trodelvy the first ADC-based backbone across PD-L1 status.

Portugal medicinal cannabis exports reached 66,305 kg in the first half of 2026, according to INFARMED, already 83% of the 79,883 kg shipped across all of 2025. The country’s medicines regulator published the figures in its mid-year report on the sector, which also shows cultivation and manufacturing licences easing back after several years of rapid expansion. Portugal began regulating medicinal cannabis in 2018, when the Assembly of the Republic approved a law covering marketing authorisations, prescribing and pharmacy dispensing. A […]

💊 Can generic medicines deliver €300 million in savings for Portugal? Portugal is targeting major cost reductions in its healthcare system by accelerating the uptake of generic medicines, aiming to improve affordability and sustainability. This move highlights strategic efforts in market access and cost-effectiveness within the pharmaceutical sector. Read the full analysis to see what it means for stakeholders. #SyenzaNews #pharmaceuticals #MarketAccess #costeffectiveness

🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security? The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures. Read the full analysis to see what it means for pricing, supply chains and market access. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

How can blended capital unlock breakthroughs in pediatric cancer treatments? Developing drugs for childhood cancers faces unique challenges—small patient populations, high risks, and limited commercial returns often deter traditional investors. This article examines why combining public grants, venture funding, and philanthropic support is critical to advancing therapies in oncology. Read the full analysis to explore innovative financing models driving progress. #SyenzaNews #oncology #biotechnology #innovation #HealthEconomics

📉 Are prescription drug prices finally easing? A new analysis reveals a 3.1% decline, with potential ripple effects on market access, reimbursement strategies, and overall pharmaceutical economics. Read the full breakdown to see what it means for stakeholders. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

The European Medicines Agency’s Management Board met in Amsterdam on 10 and 11 June 2026. The European Commission reported that the first EU joint clinical assessment report appeared on 9 June 2026. Since the Health Technology Assessment Regulation took effect in January 2025, 18 JCAs have started. Seven Joint Scientific Consultations have finished under the Regulation, and the first JCAs for medical devices and in vitro diagnostics will begin in June 2026. Initiative Status Timing First EU joint clinical assessment […]